Merck’s two-drug HIV regimen hits phase 3 success
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
SOMA Color Mind is designed to simplify and accelerate color setup directly on the printing press
The move is expected to be crucial during health crises
Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion
The initiative aims to connect startups and tech companies with its business units,
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
Subscribe To Our Newsletter & Stay Updated